top of page

GARDASIL 9 SUSPENSION FOR INJECTION

Product details

Registration number: SIN15141P

Classification: Prescription Only

Active ingredients:

  • Human Papillomavirus Type 11 L1 Protein
  • Human Papillomavirus Type 16 L1 Protein
  • Human Papillomavirus Type 18 L1 Protein
  • Human Papillomavirus Type 31 L1 Protein
  • Human Papillomavirus Type 33 L1 Protein
  • Human Papillomavirus Type 45 L1 Protein
  • Human Papillomavirus Type 52 L1 Protein
  • Human Papillomavirus Type 58 L1 Protein
  • Human Papillomavirus Type 6 L1 Protein

Strength:

  • 40 mcg
  • 60 mcg
  • 40 mcg
  • 20 mcg
  • 20 mcg
  • 20 mcg
  • 20 mcg
  • 20 mcg
  • 30 mcg

Dosage form: INJECTION, SUSPENSION

Route: INTRAMUSCULAR

Registrant: MSD PHARMA (SINGAPORE) PTE. LTD.

ATC code: J07BM03

HSA approval date: 16 December 2016

Manufacturer(s):

  • Merck Sharp & Dohme LLC (Bulk Production & Primary Packager)
  • MSD International GmbH T/A MSD Ireland (Carlow) (Bulk Production & Primary Packager)

Manufacturing country/countries: UNITED STATES; IRELAND

What are the HSA registration number and classification for GARDASIL 9 SUSPENSION FOR INJECTION?

According to the HSA dataset updated 7 August 2026:

Registration number: SIN15141P

Classification: Prescription Only

Source for this answer

What active ingredients and strength are recorded for GARDASIL 9 SUSPENSION FOR INJECTION?

According to the HSA dataset updated 7 August 2026:

Active ingredients:

  • Human Papillomavirus Type 11 L1 Protein
  • Human Papillomavirus Type 16 L1 Protein
  • Human Papillomavirus Type 18 L1 Protein
  • Human Papillomavirus Type 31 L1 Protein
  • Human Papillomavirus Type 33 L1 Protein
  • Human Papillomavirus Type 45 L1 Protein
  • Human Papillomavirus Type 52 L1 Protein
  • Human Papillomavirus Type 58 L1 Protein
  • Human Papillomavirus Type 6 L1 Protein

Strength:

  • 40 mcg
  • 60 mcg
  • 40 mcg
  • 20 mcg
  • 20 mcg
  • 20 mcg
  • 20 mcg
  • 20 mcg
  • 30 mcg

Ingredients and strengths are listed separately as recorded by HSA; their positions do not establish a one-to-one match. This is not a dosing instruction.

Source for this answer

What dosage form and route are recorded for GARDASIL 9 SUSPENSION FOR INJECTION?

According to the HSA dataset updated 7 August 2026:

Dosage form: INJECTION, SUSPENSION

Route: INTRAMUSCULAR

Source for this answer

Who is the recorded registrant for GARDASIL 9 SUSPENSION FOR INJECTION?

According to the HSA dataset updated 7 August 2026:

Registrant: MSD PHARMA (SINGAPORE) PTE. LTD.

Source for this answer

Which manufacturers and countries are listed for GARDASIL 9 SUSPENSION FOR INJECTION?

According to the HSA dataset updated 7 August 2026:

Manufacturer(s):

  • Merck Sharp & Dohme LLC (Bulk Production & Primary Packager)
  • MSD International GmbH T/A MSD Ireland (Carlow) (Bulk Production & Primary Packager)

Manufacturing country/countries: UNITED STATES; IRELAND

Source for this answer

Where can I look up GARDASIL 9 SUSPENSION FOR INJECTION in the HSA register?

Open HSA’s therapeutic product register and search for registration number SIN15141P or the exact product name GARDASIL 9 SUSPENSION FOR INJECTION. The general register link does not preselect this product.

Source for this answer

What are the source dates for this GARDASIL 9 SUSPENSION FOR INJECTION record?

This record is from HSA’s List of Registered Therapeutic Products on data.gov.sg. Dataset update: 7 August 2026. Retrieval date: 13 November 2026.

The dataset date is a snapshot date, not a separate current-register check for every product. Later direct checks are recorded separately.

Source for this answer

Has this GARDASIL 9 SUSPENSION FOR INJECTION record had a separate HSA register check?

No separate current-register check is recorded for this product. Its presence in the imported dataset does not establish its current registration status.

Search the HSA register using SIN15141P for the latest record.

Source for this answer

Sources and dates

HSA dataset: 2026. Updated: 13 November 2026.

Factual product information only; no dosing, treatment or suitability advice.

Updated and reviewed by: Dr Joel Lim MBChB UK (PG Dip Dermatology), Resident Physician.

bottom of page